An immunomodulator with antineoplastic and angiogenesis inhibitor activity. A substance being studied in the treatment of prostate cancer, multiple myeloma, and other types of cancer. CC-4047 is a form of the drug thalidomide. It stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. CC-4047 is a type of angiogenesis inhibitor and a type of immunomodulatory agent.
Mode of Action:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs